LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.02 3.03

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.01

Max

1.03

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Aktsiakasum	-0.27
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	5.5M -32M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+413.59% upside

Turustatistika
By TradingEconomics
Turukapital	-13M 112M
Eelmine avamishind	-2.01
Eelmine sulgemishind	1.02

Uudiste sentiment

By Acuity

50%

171 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. nov 2025, 22:42 UTC

Market Talk

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21. nov 2025, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

21. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. nov 2025, 21:47 UTC

Market Talk

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21. nov 2025, 21:43 UTC

Market Talk

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21. nov 2025, 20:18 UTC

Market Talk

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21. nov 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21. nov 2025, 19:48 UTC

Market Talk

Precious Metals Fall for the Week -- Market Talk

21. nov 2025, 19:44 UTC

Tulu

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21. nov 2025, 19:37 UTC

Market Talk

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21. nov 2025, 19:27 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

21. nov 2025, 19:27 UTC

Market Talk

Tulu

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21. nov 2025, 19:20 UTC

Market Talk

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21. nov 2025, 18:44 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21. nov 2025, 18:37 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21. nov 2025, 18:34 UTC

Market Talk

Tulu

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21. nov 2025, 18:28 UTC

Tulu

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21. nov 2025, 18:03 UTC

Market Talk

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21. nov 2025, 17:24 UTC

Market Talk

Global Equities Roundup: Market Talk

21. nov 2025, 17:24 UTC

Market Talk

Intuit Seen on Path to Increase Growth -- Market Talk

21. nov 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. nov 2025, 17:05 UTC

Market Talk

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21. nov 2025, 16:56 UTC

Market Talk

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21. nov 2025, 16:47 UTC

Market Talk

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21. nov 2025, 16:35 UTC

Omandamised, ülevõtmised, äriostud

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21. nov 2025, 16:09 UTC

Tulu

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21. nov 2025, 15:59 UTC

Market Talk

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

21. nov 2025, 15:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. nov 2025, 15:23 UTC

Market Talk

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

21. nov 2025, 15:17 UTC

Market Talk

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

413.59% tõus

12 kuu keskmine prognoos

Keskmine 5.29 USD 413.59%

Kõrge 8 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

171 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.